November 2016November 2016
New Product - Zepatier
Zepatier (elbasvir/ grazoprevir) is a fixed-dose combination of direct-acting antiviral agents against the hepatitis C virus.Elbasvir is an HCV NS5A inhibitor and grazoprevir is a hepatitis C virus (HCV) NS3/4A protease inhibitor. Zepatier is indicated for the treatment of chronic hepatitis C genotype 1 or 4 infection in adults. Zepatier is contraindicated in patients with moderate hepatic impairment (Child-Pugh B) due to a lack of clinical safety and efficacy experience in this patient population and the expected increase in grazoprevir plasma concentration. Zepatier is contraindicated in patients with severe hepatic impairment (Child-Pugh C) due to the expected significantly increased grazoprevir plasma concentration and the increased risk of alanine aminotransferase (ALT) elevations. Zepatier is contraindicated with inhibitors of organic anion transporting polypeptides 1B1/3 (OATP1B1/3) that are known or expected to significantly increase grazoprevir plasma concentrations, strong inducers of cytochrome P450 3A (CYP3A), and efavirenz. Medicines that are contraindicated with Zepatier include: Anticonvulsants (phenytoin, carbamazepine); Antimycobacterials (rifampicin); Herbal products (St. John’s Wort (Hypericum perforatum); HIV medications (efavirtenz, atazanavir, darunavir, lopinavir, saquinavir, and tipranavir); Immunosuppressants (cyclosporine). If Zepatier is administered with ribavirin, the contraindications to ribavirin also apply to this combination regimen. Zepatier tablets containing 50 mg elbasvir and 100 mg grazoprevir is available in packs of 28’s.
Copyright © MIMS Australia Pty Ltd. All rights reserved.
MIMS Australia
Level 2, 1 Chandos Street
St Leonards NSW 2065
Phone: 1800 800 629
info@mims.com.au
www.mims.com.au